American Journal of Cardiovascular Drugs

, Volume 11, Issue 5, pp 335–346 | Cite as

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Fimasartan Following Single and Repeated Oral Administration in the Fasted and Fed States in Healthy Subjects

  • Yong Ha Chi
  • Howard Lee
  • Soo Heui Paik
  • Joo Han Lee
  • Byoung Wook Yoo
  • Ji Han Kim
  • Hyun Kwang Tan
  • Sang Lin Kim
Original Research Article


Background and Objectives

Fimasartan (BR-A-657) is a novel, non-peptide angiotensin II receptor antagonist with a selective type I receptor blockade effect. Two first-in-human studies investigated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of fimasartan.


Fasted single oral tablet doses of fimasartan 20–480 mg or placebo were administered to 40 healthy male subjects (aged 19–54 years) in a double-blind, randomized, sequential-group design. Subjects receiving fimasartan 240 mg also received the same treatment in the fed state after an interval of 7 days. In another study, oral tablet doses of fimasartan 120 and 360 mg or placebo were given once daily for 7 days to groups of eight fasted healthy male subjects (aged 20–55 years) in a double-blind, randomized, sequential-group design. Safety and tolerability were assessed. The PK and PD of fimasartan were also evaluated and compared for the different doses.


Fimasartan was safe and well tolerated, but with an increased incidence of low BP and postural dizziness for the 360 mg dose after repeated administration. Fimasartan produced increases in plasma renin activity, angiotensin I and II, which were not dose dependent. Maximal increases occurred between 6 and 8 hours post-dose, lasting up to 48 hours. Fimasartan was absorbed rapidly after all doses and had a multiphasic distribution. Two peaks in the plasma concentration-time profile were observed in most subjects. Steady state was achieved after three doses, and accumulation was minimal after repeated doses for 7 days (24–30%). The effective half-life ranged from 9.84 to 13.2 hours. The systemic exposure of fimasartan was dose proportional, and no marked food effect was noted after administration of 240 mg in the fed state. Urinary excretion of fimasartan was very low (1.74–2.51%), suggesting non-renal elimination.


Fimasartan had a good safety profile and was well tolerated after fasted single oral doses of 20–480 mg, a fed single oral dose of 240 mg, and fasted repeated oral doses of 120 and 360 mg in healthy subjects. In addition, the PK and PD of fimasartan in this population were well characterized. Further studies are needed to evaluate the safety, efficacy, and dose-response relationship of fimasartan in patients with hypertension.


Plasma Renin Activity Candesartan Mean Residence Time Healthy Male Subject Eprosartan 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The studies presented in this manuscript were funded by Boryung Pharmaceutical Co., Ltd. Data from these studies were previously reported, in part, in posters at the 2005 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics in Orlando, FL, USA. Yong Ha Chi, Byoung Wook Yoo, Soo Heui Paik, Joo Han Lee, Hyun Kwang Tan, Sang Lin Kim, and Ji Han K im are employees of Boryung Pharmaceutical Co., Ltd. The authors have no conflicts of interest to declare.


  1. 1.
    Sohn Y. Crystal forms of an angiotensin II receptor antagonist BR-A657. J Therm Anal Cal 2007; 89 (3): 799–802.CrossRefGoogle Scholar
  2. 2.
    Boryung Pharm Co. Ltd SK. Label for Kanarb (fimasartan potassium). Data on file, 2010.Google Scholar
  3. 3.
    Boryung Pharm Co. Ltd SK. Investigator’s brochure for fimasartan. Data on file, 2006.Google Scholar
  4. 4.
    Hollenberg NK, Guidi E. ACE inhibitors and renal vascular responses in the spontaneously hypertensive rat. J Cardiovasc Pharmacol Ther 1998; 3 (2): 161–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Lane A, Engmann E, Bryson S, et al. Single dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist [abstract]. Clin Pharmacol Ther 2005; 77 (2): 59.CrossRefGoogle Scholar
  6. 6.
    Lane A, Kleinermanns D, Bryson S, et al. Multiple dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist [abstract]. Clin Pharmacol Ther 2005; 77 (2): 58.CrossRefGoogle Scholar
  7. 7.
    Boxenbaum H, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol 1995; 35 (8): 763–66.PubMedGoogle Scholar
  8. 8.
    Hummel J, McKendrick S, Brindley C, et al. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat 2009; 8 (1): 38–49.PubMedCrossRefGoogle Scholar
  9. 9.
    Brown H, Prescott R. Applied mixed models in medicine. Wiley, West Sussex, England, 2006.CrossRefGoogle Scholar
  10. 10.
    Catt KJ, Cain MD, Zimmet PZ, et al. Blood angiotensin II levels of normal and hypertensive subjects. Br Med J 1969; 1 (5647): 819–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the reninangiotensin-aldosterone system in hypertensive patients. Hypertension 1995; 25 (1): 37–46.PubMedCrossRefGoogle Scholar
  12. 12.
    Criscione L, Bradley WA, Buhlmayer P, et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995; 13 (3): 230–50.CrossRefGoogle Scholar
  13. 13.
    Kaplan NM. Angiotensin II-receptor blockers: will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension? J Hum Hypertens 2000; 14 Suppl. 1: S87–90.PubMedCrossRefGoogle Scholar
  14. 14.
    Reid IA, Morris BJ, Ganong WF. The renin-angiotensin system. Annu Rev Physiol 1978;40:377–410.PubMedCrossRefGoogle Scholar
  15. 15.
    Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14 Suppl. 1: S73–86.PubMedCrossRefGoogle Scholar
  16. 16.
    Pedersen PV, Miller R. Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci 1980; 69 (4): 394–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Zhou H. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol 2003; 43 (3): 211–27.PubMedCrossRefGoogle Scholar
  18. 18.
    Veng PP. Pharmacokinetic analysis by linear system approach. I: Cimetidine bioavailability and second peak phenomenon. J Pharm Sci 1981; 70 (1): 32–8.CrossRefGoogle Scholar
  19. 19.
    Beermann B. Value of plasma-digoxin estimation [letter]. Lancet 1973; 1 (7799): 375.PubMedCrossRefGoogle Scholar
  20. 20.
    Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25 (3): 358–71.PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Yong Ha Chi
    • 1
  • Howard Lee
    • 2
    • 3
  • Soo Heui Paik
    • 1
  • Joo Han Lee
    • 1
  • Byoung Wook Yoo
    • 1
  • Ji Han Kim
    • 1
  • Hyun Kwang Tan
    • 1
  • Sang Lin Kim
    • 1
  1. 1.Central Research Institute, Boryung Pharm. Co., LtdDanwon-gu, Ansan-si, Gyeonggi-doSouth Korea
  2. 2.Center for Drug Development Science, Department of Bioengineering and Therapeutic Sciences, School of PharmacyUniversity of California San FranciscoSan FranciscoUSA
  3. 3.Department of Bioengineering and Therapeutic SciencesUniversity of California Washington CenterUSA

Personalised recommendations